149 related articles for article (PubMed ID: 35768900)
1. Incidentally identified left ventricular apical aneurysm in a patient with Fabry disease.
Yim J; Gin K; Tsang TSM; Luong C; Lehman A; Ong K; Tsang MYC; Jue J; Nair P; Nasmith T; Yeung DF
Echocardiography; 2022 Aug; 39(8):1131-1137. PubMed ID: 35768900
[TBL] [Abstract][Full Text] [Related]
2. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
3. Arrhythmias in Fabry cardiomyopathy.
Acharya D; Doppalapudi H; Tallaj JA
Card Electrophysiol Clin; 2015 Jun; 7(2):283-91. PubMed ID: 26002392
[TBL] [Abstract][Full Text] [Related]
4. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
5. Detection of preclinical left ventricular dysfunction in Fabry disease: the contribution of tissue Doppler.
Fiuza M; Avó LB; Oliveira EI; Gonçalves S; Lopes MG
Rev Port Cardiol; 2006 Jun; 25(6):613-37. PubMed ID: 17019980
[TBL] [Abstract][Full Text] [Related]
6. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
7. Pulse-cancellation echocardiography in Fabry disease diagnosis.
Joye E; Zheng WQ; Torosoff M
Echocardiography; 2020 Jun; 37(6):908-912. PubMed ID: 32445405
[TBL] [Abstract][Full Text] [Related]
8. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
[TBL] [Abstract][Full Text] [Related]
9. Advanced Anderson-Fabry disease presenting with left ventricular apical aneurysm and ventricular tachycardia.
Poulin MF; Shah A; Trohman RG; Madias C
World J Clin Cases; 2015 Jun; 3(6):519-24. PubMed ID: 26090373
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
11. Histopathological evidence of Fabry disease in a female patient with left ventricular noncompaction.
Martins E; Pinho T; Carpenter S; Leite S; Garcia R; Madureira A; Oliveira JP
Rev Port Cardiol; 2014 Sep; 33(9):565.e1-6. PubMed ID: 25246064
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
[TBL] [Abstract][Full Text] [Related]
13. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
14. Arrhythmias in Fabry cardiomyopathy.
Acharya D; Robertson P; Kay GN; Jackson L; Warnock DG; Plumb VJ; Tallaj JA
Clin Cardiol; 2012 Dec; 35(12):738-40. PubMed ID: 22886820
[TBL] [Abstract][Full Text] [Related]
15. The Fabry cardiomyopathy - diagnostic approach and current treatment.
Weidemann F; Ertl G; Wanner C; Krämer J
Curr Pharm Des; 2015; 21(4):473-8. PubMed ID: 25483948
[TBL] [Abstract][Full Text] [Related]
16. Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status.
Morris DA; Blaschke D; Canaan-Kühl S; Krebs A; Knobloch G; Walter TC; Haverkamp W
Int J Cardiovasc Imaging; 2015 Feb; 31(2):301-13. PubMed ID: 25315709
[TBL] [Abstract][Full Text] [Related]
17. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
19. Fabry Cardiomyopathy: Current Practice and Future Directions.
Yim J; Yau O; Yeung DF; Tsang TSM
Cells; 2021 Jun; 10(6):. PubMed ID: 34204530
[TBL] [Abstract][Full Text] [Related]
20. Mechanical dispersion in Fabry disease assessed with speckle tracking echocardiography.
Cianciulli TF; Saccheri MC; Rísolo MA; Lax JA; Méndez RJ; Morita LA; Beck MA; Kazelián LR
Echocardiography; 2020 Feb; 37(2):293-301. PubMed ID: 31957094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
